Drug Database
AS

AS0-3B (AS03B1 / AS03B)

✓ Approved

GSK · therapeutic agent

What is AS0-3B?

AS0-3B is a therapeutic agent developed by GSK. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesAS03B1, AS03B
CompanyGSK
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, GSK

Therapeutic Indications

AS0-3B is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedRSC advances2026-11-12

Push-pull luminescent imidazole derivatives: ICT enables efficient picric acid sensing.

Dey Mayuri M, Bhattacharyya Arghyadeep A, Roy Swarup S, Majumdar Swapan S

Two push-pull fluorophores (3a-b) based on a tri-substituted imidazole core appended with donor-acceptor groups were successfully synthesized by the catalysis of Amberlite IR 120H+ and were fully characterized by NMR and mass spectral analyses. The synthesized compounds exhibit strong luminescent properties due to their donor-acceptor (push-pull) electronic structures and possess pronounced excited-state charge transfer characteristics, as evidenced by steady-state and time-resolved spectroscopic experiments. Imidazole incorporated with donor groups in the phenyl rings at the 4- and 5-positions (3b) shows a greater extent of charge transfer and emits yellow color in polar solvents like DMSO and acetonitrile. Both the fluorophores were found to act as sensors of picric acid in the solution phase with a very low detection level (nM) by static quenching of the fluorescence emission mechanism. The sensitivity of the detection of picric acid by 3b was found to be almost 1000 fold higher than that by 3a, and the response time of 3b towards picric acid was ∼3 times faster than that of 3a.

PMID 43017050
Read full article →
PubMedBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas2026-11-12

Assessment of physical activity level and quality of life in patients with chronic kidney disease in stages 3b and 4.

Santos F T Dos FTD, Santos C G S CGS, Barreto F C FC, Fernandez R R

The progressive decline in renal function in chronic kidney disease (CKD) is associated with multiple complications that affect the quality of life (QoL) of patients. However, physical activity may improve clinical outcomes. This study aimed to evaluate and correlate the physical activity levels of patients with CKD stages 3b and 4 with their QoL and risk of disease progression. This cross-sectional observational study included 50 patients with CKD stages 3b or 4. Physical activity levels were assessed using the International Physical Activity Questionnaire. QoL was evaluated using the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) questionnaire, combined with the sit-to-stand and handgrip strength tests. The risk of CKD progression was estimated based on the degree of albuminuria. Only 28% of the participants were classified as physically active. A significant association was observed between physical activity level and CKD stage. Most physically active participants had albuminuria of ≤30 mg/g, indicating a lower risk of CKD progression. Participants with A2 albuminuria were more likely to be inactive than those with A1 albuminuria (P=0.01). Additionally, active individuals demonstrated higher mean scores across most SF-36 domains and superior performance in the handgrip and sit-to-stand tests. A positive correlation was identified between physical activity and QoL, with the strongest correlations observed in the vitality (r=0.42; P<0.01) and general health (r=0.43; P<0.01) domains. Higher physical activity levels are associated with better QoL and lower albuminuria, suggesting a reduced risk of disease progression. These findings highlight the importance of promoting physical activity among patients with CKD stages 3b or 4.

PMID 43018011
Read full article →
PubMedDalton transactions (Cambridge, England : 2003)2026-11-12

Activation of CO2 and (COCl)2 by (TMS)2N(η1-Cp*)SiSi(η1-Cp*)N(TMS)2.

Gothe Prachi P, Kushwaha Vikash V, Khan Shabana S

In this work, we report the reactivity of disilene [(TMS)2N(η1-Cp*)SiSi(η1-Cp*)N(TMS)2] (1) towards CO2 and oxalyl chloride (COCl)2. The reaction of 1 with CO2 produced a highly strained disilaoxirane (2) via CO extrusion, while oxalyl chloride yielded oxidative addition products (3a) and (3b). Both products were characterised using multinuclear NMR spectroscopy and single-crystal X-ray crystallography.

PMID 43018435
Read full article →
PubMedFrontiers in cardiovascular medicine2026-11-12

Development and evaluation of a transesophageal echocardiography-derived left atrial appendage structure-function coupling index across the atrial fibrillation disease continuum.

Zhu Jianbo J, Ni Chen C, Ruan Yangnan Y, Jiang Yanfeng Y et al.

Atrial fibrillation (AF) is a progressive disorder associated with atrial remodeling and thromboembolic risk. We developed a transesophageal echocardiography (TEE)-derived left atrial appendage (LAA) structure-function coupling index (LAA-SFCI), defined as LAA volumetric load relative to longitudinal deformation, and assessed its distribution along the AF disease continuum and its potential for risk re-stratification of patients without documented AF. This single-center, prospective, cross-sectional study included 267 patients undergoing clinically indicated TEE, classified by the 2023 American College of Cardiology/American Heart Association/American College of Clinical Pharmacy/Heart Rhythm Society (ACC/AHA/ACCP/HRS) framework as Stage 1 (n = 68), Stage 2 (n = 65), Stage 3a (n = 66), or Stage 3b (n = 68). Seven candidate LAA-SFCIs were calculated as the LAA volume index (LAA-VI) divided by a functional measure, and the principal index was selected by ordinal logistic regression using the Akaike information criterion. Discrimination was compared using the DeLong test and internally validated by bootstrapping, and patients without documented AF (Stages 1-2) were stratified by the exploratory cutoff. LAA-VI/LAA-GLS (LAA global longitudinal strain) provided the best model fit and rose across AF stages from 0.33 ± 0.11 to 0.86 ± 0.36 (mL/m2)/% (P < 0.001). In ordinal regression with the log-transformed index, each 1-SD increase remained associated with higher AF stage after adjustment for age, sex, body mass index, left ventricular ejection fraction, and left atrial volume index (odds ratio 11.04, 95% confidence interval 7.17-16.98). For Stage 1-2 versus Stage 3a-3b, its area under the curve (0.904; optimism-corrected 0.900) was significantly higher than those of LAA-VI (0.661) and LAA-GLS (0.824) (both DeLong P < 0.001). Among 133 patients without documented AF, 18 (13.5%) exceeded the cutoff of 0.460 (mL/m2)/%; these patients did not differ from the others in left atrial volume index or age. In this cross-sectional study, LAA-VI/LAA-GLS characterized LAA structure-function uncoupling along the AF disease continuum. In patients without documented AF undergoing clinically indicated TEE, it identified a subgroup with an AF-like LAA phenotype not captured by conventional atrial size measures. These findings are hypothesis-generating and require external validation and longitudinal follow-up to determine their prognostic value.

PMID 43016419
Read full article →
PubMedChildhood kidney diseases2026-11-12

Target antigens and antigen-specific clinical phenotypes in pediatric membranous nephropathy.

Lee Jiwon M JM, Yang Eun Mi EM

Primary membranous nephropathy (MN) is rare in childhood and increasingly understood as a spectrum of antigen- defined diseases. The distribution of glomerular target antigens and their clinical relevance in pediatric MN remain poorly defined. We systematically reviewed English-language reports of biopsy-confirmed MN diagnosed at ≤18 years of age. Databases were searched through August 1, 2026. Tissue-antigen and serum-antibody evidence were analyzed separately, overlapping cohorts were audited, and tissue M-type phospholipase A2 receptor (PLA2R) prevalence was pooled with a binomial-normal random- effects generalized linear mixed model. Twenty-three reports were included. Ten independent tissue cohorts comprised 196 patients; 74 were PLA2R-positive (crude proportion, 37.8%). Pooled tissue PLA2R prevalence was 38.5% (95% confidence interval, 25.7%-53.2%; 95% prediction interval, 8.2%-81.5%; model-based I2=70.1%). Several cohorts suggested greater PLA2R positivity in older children. Exostosin 1 and 2 were linked to autoimmune or lupus-like features. All seven neural epidermal growth factor-like 1-positive patients were female and associated with environmental exposure. Semaphorin 3B positivity suggested early-childhood onset and male predominance. Current evidence is insufficient to use antigen status alone for prognostic or treatment stratification in pediatric MN. Nevertheless, antigen typing may refine diagnosis and etiologic evaluation by prompting assessment for autoimmunity or relevant exposures. Serial anti-PLA2R measurement may support patient monitoring although tissue and serum findings are not interchangeable.

PMID 43016257
Read full article →
PubMedAnnals of medicine and surgery (2012)2026-11-12

Outcomes of living-donor liver transplantation for Budd-Chiari syndrome: a retrospective comparative cohort study.

Bashir Hafiz Aamir HA, Ullah Kaleem K, Uddin Shams S, Baloch Umar U et al.

Living-donor liver transplantation (LDLT) for Budd-Chiari syndrome (BCS) poses unique technical and management challenges. The outcomes of LDLT for BCS, compared with other indications, are unclear and warrant further elucidation. Data from 26 BCS recipients (20 adults and 6 children) who underwent LDLT between January 2019 and June 2023 were retrospectively analyzed to evaluate outcomes. In addition, adult BCS recipients (n = 20) were compared with a matched control group of recipients (n = 50) transplanted for other indications for perioperative parameters and outcomes. The median age of adult BCS recipients was 25 years, while that of pediatric patients were 11 years. The majority (84.62%) of BCS recipients were male, and all (100%) had a primary form of the disease. The most common symptom was ascites (73.07%). Only five patients (19.23%) underwent radiological intervention before transplantation. Retrohepatic caval replacement was performed in five patients (19.23%). Clavien-Dindo major morbidity (grade 3b/4) was documented in eight patients (30.76%). Hepatic arterial thrombosis and venous outflow obstruction were documented in three patients (11.53%) each. Compared with the control group, BCS recipients experienced prolonged cold ischemia and operative time, heightened blood loss, a greater need for transfusions, a longer hospital stay, and a higher incidence of outflow obstruction (P < 0.05). The BCS cohort had 1-year and 3-year survival rates of 84.6 and 73.1%, respectively, compared with 90 and 82% in the non-BCS group (log-rank, P = 1.08). Although patients with BCS present technical challenges, they can achieve outcomes comparable to those of non-BCS recipients with a good operative strategy, optimal postoperative anticoagulation, and regular surveillance for outflow complications.

PMID 43017660
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about AS0-3B